On 5 February, RXi Pharmaceuticals Corporation (NASDAQ: RXII), announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone™ with Hapten Pharmaceuticals, LLC. On Tuesday shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII) closed at $1.26.
On 3 February, Kite Pharma, Inc., (NASDAQ:KITE) announced the appointments of Salah D. Kivlighn, Ph.D., as Vice President, Marketing, and Anthony J. Polverino, Ph.D., as Vice President, Research. Kite Pharma, Inc. (NASDAQ:KITE) in last trading activity increased 5.41% to close at $63.88. Company weekly performance is 0.30% while its quarterly performance stands at 38.90%. Kite Pharma, Inc. (NASDAQ:KITE) is -28.39% away from its 52 week high.
On 30 January, EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), announced the pricing of an underwritten public offering of 9.6 million shares of its common stock, offered at a price to the public of $5.00 per share. On last trading day EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) increased 5.72% to close at $5.91. Its volatility for the week is 10.96% while volatility for the month is 10.89%. EPRS’s sales growth for past 5 years was 3.60% and its EPS growth for past 5 years was 30.60%. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) monthly performance is -27.31%.
For the first quarter ended December 31, 2014, Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) reported a net loss of approximately $4.6 million, or $0.18 per share, compared with $2.0 million, or $0.10 per share, in the first quarter of 2013. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) has 2.10% insider ownership while its institutional ownership stands at 23.70%. In last trading activity company’s stock closed at $7.87.
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) announced its acquisition of Chinese PLA General Hospital’s (“PLAGH”, Beijing, also known as “301 Hospital”) Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor’s (EGFR or HER1) Immuno-Oncology patents. On last trading day Cellular Biomedicine Group Inc. (NASDAQ:CBMG) increased 0.85% to close at $23.60. Its volatility for the week is 12.86% while volatility for the month is 8.90%. CBMG’s EPS growth for past 5 years was -19.20%. Cellular Biomedicine Group Inc. (NASDAQ:CBMG) monthly performance is 46.40%.